Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)
Primary Purpose
Peripheral Arterial Disease
Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
Jetstream Atherectomy System
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring Superficial Femoral Artery, Proximal Popliteal Artery, Endovascular therapy, Atherectomy
Eligibility Criteria
Inclusion Criteria:
- Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2-4
Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA of which meet all of the following criteria:
- Calcified lesions with degree of stenosis ≥70% or occlusions
- Guidewire must cross lesion(s) within the true lumen, without a sub-intimal course
- Vessel diameter ≥3.0 mm and ≤6.0 mm
- Total lesion length (or series of lesions) ≤150mm
- Target lesion located at least 3 cm above the inferior edge of the femur by visual estimate
- Patent infrapopliteal and popliteal artery
Exclusion Criteria:
- Target lesion/vessel with in-stent restenosis
- Target lesion/vessel previously treated with drug-coated balloon <12 months prior to the procedure
- Target lesion/vessel previously treated with any stent placement, atherectomy, laser or other debulking devices prior to the procedure
- Subjects who have undergone surgery or endovascular of the SFA/PPA in the target vessel to treat atherosclerotic disease within 3 months prior to the index procedure
- Use of drug-coated devices, atherectomy, laser or other debulking devices other than the Jetstream System, chronic total occlusion (CTO) devices or cutting balloon, Angioscore or similar devices in the target limb SFA/PPA during the index procedure
- History of major amputation in the target limb
- Subject has a history of coagulopathy or hypercoagulable bleeding disorder
- Subject with untreatable hemorrhagic disease or platelet count <80,000mm3 or >600,000mm3 as baseline assessment.
- Concomitant renal failure with a serum creatinine >2.0 mg/dL
- Receiving dialysis or immunosuppressant therapy
- History of myocardial infarction, or stroke/cerebrovascular accident (CVA) within 6 months prior to study enrollment
- Unstable angina pectoris at the time of the enrollment
- Septicemia at the time of enrollment
- Presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure
- Presence of aneurysm in the target vessel
- Acute ischemia and/or acute thrombosis of the SFA/PPA prior to the index procedure
- Perforated vessel as evidenced by extravasation of contrast media prior to the index procedure
Sites / Locations
- Nagoya Kyoritsu Hospital
- Kokura Memorial Hospital
- Iwaki Kyouritsu Hospital
- Tokeidai Memorial Hospital
- Kansai Rosai Hospital
- Saiseikai Yokohama-City Eastern Hospital
- Kishiwada Tokushukai Hospital
- Kasukabe Chuo General Hospital
- Miyazaki Medical Association Hospital
- Nagano Red Cross Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Jetstream Atherectomy System
Arm Description
Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Outcomes
Primary Outcome Measures
Primary Patency Rate
Secondary Outcome Measures
Full Information
NCT ID
NCT02733653
First Posted
March 24, 2016
Last Updated
December 17, 2018
Sponsor
Boston Scientific Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02733653
Brief Title
Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)
Official Title
A Prospective, Multicenter, Single-arm Clinical Trial of Jetstream Atherectomy System for the Treatment of Japanese Patients With Symptomatic Occlusive Atherosclerotic Lesions in the Superficial Femoral and/ or Proximal Popliteal Arteries
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
May 25, 2016 (Actual)
Primary Completion Date
June 29, 2017 (Actual)
Study Completion Date
December 20, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston Scientific Corporation
4. Oversight
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral artery (SFA) and/or proximal popliteal arteries (PPA).
Detailed Description
A prospective, multicenter, single-arm trial evaluating the safety and efficacy of the Jetstream Atherectomy System in the treatment of symptomatic occlusive atherosclerotic lesions ≤150 mm in length located in the femoropopliteal arteries in subjects with symptoms classified as Rutherford categories 2-4.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
Keywords
Superficial Femoral Artery, Proximal Popliteal Artery, Endovascular therapy, Atherectomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Jetstream Atherectomy System
Arm Type
Experimental
Arm Description
Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Intervention Type
Device
Intervention Name(s)
Jetstream Atherectomy System
Intervention Description
A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
Primary Outcome Measure Information:
Title
Primary Patency Rate
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Procedural Success Rate
Description
Bailout stenting or surgical procedure during the index procedure is not needed
Time Frame
during procedure
Title
Rate of Distal Emboli Requiring Additional Treatment
Time Frame
during procedure or within 24 hours post-index procedure
Title
Reduction in Lesion Stenosis
Description
The difference between the percent stenosis prior to treatment with Jetstream and the percent stenosis following treatment with Jetstream.
Time Frame
during procedure
Title
Major Adverse Event (MAE) Rate
Description
All-cause death through 1 month, and/or target limb major amputation and/or Target Lesion Revascularization (TLR) through 12 months
Time Frame
1 month, 6 months and 12 months
Title
Primary Patency
Description
Percentage (%) of lesions that reach endpoint without a hemodynamically significant stenosis on Duplex Ultrasound (DUS) and without Target Lesion Revascularization (TLR) or, bypass of the target lesion.
Time Frame
1 month, 6 months and 12 months
Title
Assisted Primary Patency
Description
Percentage (%) of lesions without TLR and those with TLR (not due to complete occlusion or by-pass) that reach endpoint without restenosis.
Time Frame
1 month, 6 months and 12 months
Title
Clinically-driven TLR Rate
Time Frame
1 month, 6 months and 12 months
Title
Clinically-driven Target Vessel Revascularization (TVR) Rate
Time Frame
1 month, 6 months and 12 months
Title
Adverse Event Rates
Time Frame
1 month, 6 months and 12 months
Title
Distribution of Rutherford Class
Description
Distribution of Rutherford Class as compared to baseline at 6 months and 12 months
Time Frame
6 months and 12 months
Title
Rate of Primary and Secondary Sustained Clinical Improvement
Time Frame
1 month, 6 months and 12 months
Title
Rate of Hemodynamic Improvement
Time Frame
1 month, 6 months and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2-4
Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA of which meet all of the following criteria:
Calcified lesions with degree of stenosis ≥70% or occlusions
Guidewire must cross lesion(s) within the true lumen, without a sub-intimal course
Vessel diameter ≥3.0 mm and ≤6.0 mm
Total lesion length (or series of lesions) ≤150mm
Target lesion located at least 3 cm above the inferior edge of the femur by visual estimate
Patent infrapopliteal and popliteal artery
Exclusion Criteria:
Target lesion/vessel with in-stent restenosis
Target lesion/vessel previously treated with drug-coated balloon <12 months prior to the procedure
Target lesion/vessel previously treated with any stent placement, atherectomy, laser or other debulking devices prior to the procedure
Subjects who have undergone surgery or endovascular of the SFA/PPA in the target vessel to treat atherosclerotic disease within 3 months prior to the index procedure
Use of drug-coated devices, atherectomy, laser or other debulking devices other than the Jetstream System, chronic total occlusion (CTO) devices or cutting balloon, Angioscore or similar devices in the target limb SFA/PPA during the index procedure
History of major amputation in the target limb
Subject has a history of coagulopathy or hypercoagulable bleeding disorder
Subject with untreatable hemorrhagic disease or platelet count <80,000mm3 or >600,000mm3 as baseline assessment.
Concomitant renal failure with a serum creatinine >2.0 mg/dL
Receiving dialysis or immunosuppressant therapy
History of myocardial infarction, or stroke/cerebrovascular accident (CVA) within 6 months prior to study enrollment
Unstable angina pectoris at the time of the enrollment
Septicemia at the time of enrollment
Presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure
Presence of aneurysm in the target vessel
Acute ischemia and/or acute thrombosis of the SFA/PPA prior to the index procedure
Perforated vessel as evidenced by extravasation of contrast media prior to the index procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kazushi Urasawa, MD, PhD
Organizational Affiliation
Tokeidai Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nagoya Kyoritsu Hospital
City
Nagoya
State/Province
Aichi
ZIP/Postal Code
454-0933
Country
Japan
Facility Name
Kokura Memorial Hospital
City
Kokura
State/Province
Fukuoka
ZIP/Postal Code
802-8555
Country
Japan
Facility Name
Iwaki Kyouritsu Hospital
City
Iwaki
State/Province
Fukushima
ZIP/Postal Code
973-8555
Country
Japan
Facility Name
Tokeidai Memorial Hospital
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
060-0031
Country
Japan
Facility Name
Kansai Rosai Hospital
City
Amagasaki
State/Province
Hyogo
ZIP/Postal Code
660-8511
Country
Japan
Facility Name
Saiseikai Yokohama-City Eastern Hospital
City
Yokohama
State/Province
Kanagawa
ZIP/Postal Code
230-8765
Country
Japan
Facility Name
Kishiwada Tokushukai Hospital
City
Kishiwada
State/Province
Osaka
ZIP/Postal Code
596-8522
Country
Japan
Facility Name
Kasukabe Chuo General Hospital
City
Kasukabe
State/Province
Saitama
ZIP/Postal Code
344-0063
Country
Japan
Facility Name
Miyazaki Medical Association Hospital
City
Miyazaki
ZIP/Postal Code
880-0834
Country
Japan
Facility Name
Nagano Red Cross Hospital
City
Nagano
ZIP/Postal Code
380-8582
Country
Japan
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)
We'll reach out to this number within 24 hrs